NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,421 | +12.8% | 57,793 | +9.0% | 0.00% | – |
| Q2 2023 | $30,505 | -96.3% | 53,034 | -95.4% | 0.00% | -100.0% |
| Q1 2023 | $816,017 | -69.3% | 1,160,930 | -1.4% | 0.00% | -50.0% |
| Q4 2022 | $2,661,821 | -29.2% | 1,177,797 | +0.3% | 0.00% | -33.3% |
| Q3 2022 | $3,759,000 | -15.4% | 1,174,585 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $4,443,000 | -34.4% | 1,169,245 | -6.9% | 0.00% | -25.0% |
| Q1 2022 | $6,768,000 | -60.3% | 1,255,601 | -0.5% | 0.00% | -60.0% |
| Q4 2021 | $17,047,000 | +41.3% | 1,261,799 | +87.8% | 0.01% | +25.0% |
| Q3 2021 | $12,068,000 | +4.1% | 671,938 | -0.6% | 0.01% | +14.3% |
| Q2 2021 | $11,594,000 | -12.9% | 675,658 | +1.5% | 0.01% | -22.2% |
| Q1 2021 | $13,315,000 | +37.9% | 665,756 | +17.2% | 0.01% | +28.6% |
| Q4 2020 | $9,657,000 | +2.6% | 568,053 | +0.1% | 0.01% | -12.5% |
| Q3 2020 | $9,414,000 | -30.4% | 567,483 | -2.9% | 0.01% | -33.3% |
| Q2 2020 | $13,532,000 | +36.1% | 584,302 | +4.9% | 0.01% | +9.1% |
| Q1 2020 | $9,941,000 | -40.4% | 556,906 | -27.9% | 0.01% | -21.4% |
| Q4 2019 | $16,679,000 | +236.3% | 772,730 | +183.8% | 0.01% | +250.0% |
| Q3 2019 | $4,959,000 | -50.1% | 272,264 | -2.5% | 0.00% | -55.6% |
| Q2 2019 | $9,937,000 | +2.0% | 279,282 | -3.7% | 0.01% | 0.0% |
| Q1 2019 | $9,741,000 | +2.8% | 289,912 | +0.6% | 0.01% | -10.0% |
| Q4 2018 | $9,474,000 | -45.6% | 288,227 | +0.9% | 0.01% | -33.3% |
| Q3 2018 | $17,410,000 | +44.8% | 285,590 | +16.0% | 0.02% | +36.4% |
| Q2 2018 | $12,022,000 | -69.1% | 246,201 | -32.8% | 0.01% | -70.3% |
| Q1 2018 | $38,951,000 | -53.6% | 366,564 | -73.9% | 0.04% | -51.9% |
| Q4 2017 | $83,981,000 | +140.0% | 1,406,257 | -3.5% | 0.08% | +126.5% |
| Q3 2017 | $34,992,000 | +17.0% | 1,458,007 | -4.7% | 0.03% | +13.3% |
| Q2 2017 | $29,910,000 | -16.7% | 1,529,950 | +0.0% | 0.03% | -30.2% |
| Q1 2017 | $35,907,000 | +96.5% | 1,529,892 | +2.7% | 0.04% | +87.0% |
| Q4 2016 | $18,271,000 | -19.9% | 1,489,045 | +12.1% | 0.02% | -23.3% |
| Q3 2016 | $22,817,000 | +25.6% | 1,328,083 | +4.0% | 0.03% | +20.0% |
| Q2 2016 | $18,165,000 | +5.3% | 1,276,593 | +1.8% | 0.02% | 0.0% |
| Q1 2016 | $17,248,000 | -15.3% | 1,254,366 | +3.8% | 0.02% | -16.7% |
| Q4 2015 | $20,359,000 | +61.3% | 1,208,204 | +4.9% | 0.03% | +50.0% |
| Q3 2015 | $12,623,000 | -9.6% | 1,151,694 | +3.2% | 0.02% | -4.8% |
| Q2 2015 | $13,963,000 | +336.3% | 1,116,130 | +283.6% | 0.02% | +320.0% |
| Q1 2015 | $3,200,000 | -28.1% | 290,949 | +1.4% | 0.01% | -28.6% |
| Q4 2014 | $4,449,000 | +20.2% | 287,042 | -6.4% | 0.01% | +16.7% |
| Q3 2014 | $3,700,000 | -4.3% | 306,530 | +1.7% | 0.01% | 0.0% |
| Q2 2014 | $3,865,000 | +2.7% | 301,481 | -2.9% | 0.01% | -14.3% |
| Q1 2014 | $3,764,000 | +1202.4% | 310,543 | +1120.7% | 0.01% | +600.0% |
| Q4 2013 | $289,000 | -10.5% | 25,440 | -17.7% | 0.00% | 0.0% |
| Q3 2013 | $323,000 | -22.2% | 30,930 | -13.8% | 0.00% | 0.0% |
| Q2 2013 | $415,000 | – | 35,902 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |